[A17-46] Pembrolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 04.01.2018
Commission awarded on 13.09.2017 by the Federal Joint Committee (G-BA).
Adult patients with locally advanced or metastatic urothelial cell carcinoma
First-line, cisplatin-based therapy unsuitable: added benefit not proven. After pretreatment with platinum-based chemotherapy: indication of considerable added benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.